ArticleMovement disorders : official journal of the Movement Disorder Society2021
Is Levodopa Response a Valid Indicator of Parkinson's Disease?
Article in Movement disorders : official journal of the Movement Disorder Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 39 citations in OpenAlex.
- Diagnostic, Prognostic Value, and Pathological Associations of Levodopa Responsiveness in Parkinson's Disease, Multiple System Atrophy, and Progressive Supranuclear Palsy.Annals of neurology · 2026Article
- Natural history and 12-month progression of multiple system atrophy in a Chinese cohort.BMC neurology · 2026Observational
- Levodopa-Induced Oculogyric Crisis in Multiple System Atrophy.Journal of movement disorders · 2026Article
- Effects of anti-parkinsonian medication on gait during internal and external rhythmic auditory cueing in PD.Frontiers in human neuroscience · 2026Article
- Moving beyond monitoring: wearable technology (PKG) for the diagnosis of Parkinson's disease.BMJ neurology open · 2026Article
- Revisiting the 2015 MDS diagnostic criteria for Parkinson disease: insights from autopsy-confirmed cases.NPJ Parkinson's disease · 2025Article
- Characteristics of responders to interventions for Parkinson disease: a scoping systematic review.Neurodegenerative disease management · 2025Article
- Dual stream transformer for medication state classification in Parkinson's disease patients using facial videos.NPJ digital medicine · 2025Article
- Asymmetry in Atypical Parkinsonian Syndromes-A Review.Journal of clinical medicine · 2024Review
- Dopa Responsiveness in Parkinson's Disease.Movement disorders clinical practice · 2024Article
- Article
- Deep learning predicts prevalent and incident Parkinson's disease from UK Biobank fundus imaging.Scientific reports · 2024Article
- Parkinson's disease updates: Addressing the pathophysiology, risk factors, genetics, diagnosis, along with the medical and surgical treatment.Annals of medicine and surgery (2012) · 2023Review
- Perry Disease: Expanding the Genetic Basis.Movement disorders clinical practice · 2023Article
- A severe neurodegenerative disease with Lewy bodies and a mutation in the glucocerebrosidase gene.NPJ Parkinson's disease · 2023Article
- Dopaminergic regulation of inflammation and immunity in Parkinson's disease: friend or foe?Clinical & translational immunology · 2023Review
- Neocortical Lewy Body Pathology Parallels Parkinson's Dementia, but Not Always.Annals of neurology · 2023Review
- The Early Treatment Phase in Parkinson's Disease: Not a Honeymoon for All, Not a Honeymoon at All?Journal of Parkinson's disease · 2023Article
- A case of Lewy body disease and anaplastic astrocytoma presenting with atypical parkinsonism.Neuropathology : official journal of the Japanese Society of Neuropathology · 2022Article
- Levodopa responsiveness in Parkinson's disease: harnessing real-life experience with machine-learning analysis.Journal of neural transmission (Vienna, Austria : 1996) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 4 countries.
Funding
Abstract
backgroundThe clinical diagnosis of Parkinson's disease (PD) requires the presence of parkinsonism and supportive criteria that include a clear and dramatic beneficial response to dopaminergic therapy. Our aim was to test the diagnostic criterion of dopaminergic response by evaluating its association with pathologically confirmed diagnoses in a large population of parkinsonian patients.
methodsWe reviewed clinical data maintained in an electronic medical record from all patients with autopsy data who had been seen in the Movement Disorders Center at Washington University, St. Louis, between 1996 and 2018. All patients with parkinsonism who underwent postmortem neuropathologic examination were included in this analysis.
resultsThere were 257 unique parkinsonian patients with autopsy-based diagnoses who had received dopaminergic therapy. Marked or moderate response to dopaminergic therapy occurred in 91.2% (166/182) of those with autopsy-confirmed PD, 52.0% (13/25) of those with autopsy-confirmed multiple systems atrophy, 44.4% (8/18) of those with autopsy-confirmed progressive supranuclear palsy, and 1 (1/8) with autopsy-confirmed corticobasal degeneration. Other diagnoses were responsible for the remaining 24 individuals, 9 of whom had a moderate response to dopaminergic therapy.
conclusionA substantial response to dopaminergic therapy is frequent but not universal in PD. An absent response does not exclude PD. In other neurodegenerative disorders associated with parkinsonism, a prominent response may also be evident, but this occurs less frequently than in PD. © 2020 International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.